Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 8/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 2/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.56 |
| ▸ | FAP | Q12884 | 1/20 | 0.56 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.56 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 2/20 | 0.55 |
| ▸ | NOS1 | P29475 | 2/20 | 0.55 |
| ▸ | NOS2 | P35228 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557415 | 1.00 | FOLH1 (0.59) | FOLH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL43811 | 1.00 | FOLH1 (0.59) | FOLH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL29397955 | 1.00 | FOLH1 (0.59) | FOLH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL43812 | 1.00 | FOLH1 (0.59) | FOLH1SLC7A5PTGS1ALPIPKM | |
| Ammonia Solution, Strong SCHEMBL3564413 | 0.98 | FOLH1 (0.58) | FOLH1SLC7A5PTGS1ALPIPKM | |
| Hydrochloric Acid SCHEMBL7591933 | 0.98 | FOLH1 (0.58) | FOLH1SLC7A5PTGS1ALPIPKM | |
| Ammonia Solution, Strong SCHEMBL3564410 | 0.98 | FOLH1 (0.58) | FOLH1SLC7A5PTGS1ALPIPKM | |
| Ammonia Solution, Strong SCHEMBL3564412 | 0.98 | FOLH1 (0.58) | FOLH1SLC7A5PTGS1ALPIPKM | |
| Hydrochloric Acid SCHEMBL7042048 | 0.98 | FOLH1 (0.58) | FOLH1SLC7A5PTGS1ALPIPKM | |
| Hydrochloric Acid SCHEMBL27695050 | 0.98 | FOLH1 (0.58) | FOLH1SLC7A5PTGS1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306692-A1 | PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-09-29 | — | — | US | claimed |
| EP-4021475-A1 | PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF | Arizona Board of Regents on behalf of the University of Arizona (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2021042064-A1 | PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-03-04 | — | — | WO | claimed |
| US-20160022636-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | claimed |
| EP-2968240-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | claimed |
| US-20140336216-A1 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | claimed |
| WO-2014152917-A2 | PHYSIOLOGICAL LIGANDS FOR GPR139 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | claimed |
| EP-0635008-B1 | PIPERAZIDES OF SUBSTITUTED PHENYLALANINE DERIVATES AS THROMBIN INHIBITORS | PENTAPHARM AG (CH) | 2002-09-04 | — | — | EP | claimed |
| EP-0635008-A1 | PIPERAZIDES OF SUBSTITUTED PHENYLALANINE DERIVATES AS THROMBIN INHIBITORS | Pentapharm A.G. (CH) | 1995-01-25 | — | — | EP | claimed |
| WO-1994018185-A1 | PIPERAZIDES OF SUBSTITUTED PHENYLALANINE DERIVATES AS THROMBIN INHIBITORS | PENTAPHARM AG (CH) | 1994-08-18 | — | — | WO | claimed |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122036607-A | Central targeting type tacrine conjugate based on transporter and preparation method and application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | TRANSFERT PLUS LP (CA) | 2026-03-26 | — | — | US | disclosed |
| EP-4673162-A1 | PATHOGEN-SPECIFIC PEPTIDE TO BLOCK VIRULENCE-RELATED SIGNALING IN CANDIDA ALBICANS | I3S - Instituto de Investigação e Inovação em Saúde, Associação (PT) | 2026-01-07 | — | — | EP | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| US-5607937-A | Piperazides of substituted phenylalanine derivatives as thrombin inhibitors | PENTAPHARM AG (CH) | 1997-03-04 | — | — | US | disclosed |
| EP-0635008-A1 | PIPERAZIDES OF SUBSTITUTED PHENYLALANINE DERIVATES AS THROMBIN INHIBITORS | Pentapharm A.G. (CH) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994018185-A1 | PIPERAZIDES OF SUBSTITUTED PHENYLALANINE DERIVATES AS THROMBIN INHIBITORS | PENTAPHARM AG (CH) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | FOLH1 2480/4885SLC7A5 1405/4885PTGS1 1907/4885 |
| US-20220306692-A1 | PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF | PTK2, LTK, LIMK2 | FOLH1 2624/4885SLC7A5 3035/4885PTGS1 3410/4885 |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | VSIG8, MICA, CD74 | FOLH1 2574/4885SLC7A5 1741/4885PTGS1 3808/4885 |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | PTK2, ILK, FPR2 | FOLH1 2927/4885SLC7A5 2200/4885PTGS1 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.